Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine and Rituximab in Hairy Cell Leukemia
NCT00412594Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2004
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine and rituximab in hairy cell leukemia (HCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Complete Response at 12 weeks, Grade 3-4 Toxicity at 1 year and 3 more. Started Jun 2004; status: recruiting.
02
Drugs
cladribinerituximab
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT00412594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412594.